Capitalizing on Opportunities in Cord Blood Industry Growth –

Overview: Over the past 12 months, the cord blood banking industry has expanded through double digit growth, due to new entrants in the cord blood banking industry as well as revenue growth at existing operations. Deeper analysis reveals that of existing cord blood banks, most fall into one of two “camps,” either experiencing flat-line growth (less than 3% per annum) or substantively building revenue (17% or more per annum).

This finding begs the questions:

•What factors are causing a substantial number of new cord blood banks to open up business? Is it the result of a profit opportunity, an effect of advances in therapeutic applications, a social response to more parents being aware of the opportunity to store cord stem cells at birth, or are other factors driving the activity?

•What will be the effect of these new entrants to the cord blood banking industry for existing competitors?

•Perhaps most critically, what are the differences among the cord blood banks that are experiencing flat-line growth, versus those that have substantively built revenue over the past 12 months?
In BioInformant’s initial version of this report, “Choices in Cord Blood Banking – Factors Influencing Parental Decision-Making,” launched April 2009, an survey of 1,200 expectant parents was used to provide a roadmap for how cord blood banks can best communicate and market their services to potential clients. The top-selling report explored the specific reasons that parents elect to store cord blood and what factors influence their decision-making in choosing a specific bank. (Click here to read the Executive Summary for the original version of the report.)

This expanded and updated version includes from the original report, as well as supplemental analysis of factors that have produced double-digit industry growth over the past year. It provides guidance on how to break through flat-line growth to become a fast-growing competitor within the cord blood industry.

Executive Summary

Overview: Cord blood banking is increasingly being used to improve and save lives. Stem cells derived from umbilical blood have been used in more than 14,000 transplants worldwide to treat a wide range of blood diseases, genetic and metabolic disorders, immunodeficiencies and various forms of cancer. However, many expectant parents still do not fully understand the significance of cord blood storage. A study published in the Journal of Reproductive Medicine shows that a third of expectant parents are unaware of the option to preserve cord blood. Of the two-thirds who have some knowledge, 74% describe themselves as “minimally informed.”
Part 1 of this market report used proprietary data-derivation techniques to analyze conditions of the Cord Blood Banking Industry. Part 2 of this report used an end-user survey of expectant parents to identify and analyze the factors involved in the decision to privately store, publicly donate, or discard cord blood at birth. More than 1,200 expectation parents answered the detailed survey. The survey initially focused on U.S. respondents, but due to international interest was expanded to include respondents from Canada, Mexico, South America, Europe, Asia, Australia, and other regions as well.

Key findings of the report includes:

•Rates of awareness by gender, income, geographic location, and education
•Sources through which expectant parents learn of cord blood preservation
•Factors influencing private vs. public storage of cord blood
•Price sensitivity and quality expectations
•Approaches for communicating with expectant parents
•Key factors influencing the decision to store cord blood
•Parental responsiveness to health statistics
•Trends in cord blood banking
•Competitive analysis of the cord blood banking industry

http://www.aarkstore.com/reports/Capitalizing-on-Opportunities-in-Cord-Blood-Industry-Growth-32359.html

Hematology Analyzer Instrumentation and Reagent Markets – Aarkstore Enterprise

Clinical hematology analyzer analysis is one of the oldest and most important sectors of clinical laboratory analysis. The hematology instrument and reagent market is centered around a group of instruments called hematology analyzers. The term clinical hematology analyzer usually refers to an automated instrument for determining the presence, number and type of cellular elements in easily collected body fluids, such as blood. However, it is not necessarily limited to these determinations. The hematology analysis always includes determination of non-cellular parameters in blood, such as hemoglobin and hematocrit. Other closely related areas of clinical interest are coagulation and flow cytometry. In fact, traditional specialization barriers, such as microbiology, hematology, blood banking, immunology and even anatomical pathology are rapidly fading both operationally and instrumentally. But for the sake of defining the subject to a reasonable size, the more traditional scope of clinical hematology analyzer will be the focus of this examination. The purpose of this Publications report is to describe the specific segments of the global clinical hematology analyzer instrumentation and reagent marketplace. The review covers those segments that are highly active in terms of innovation and growth. Specifically, this study examines the markets for small-lab, as well as highly-automated large-lab, platforms and accessory equipment, such as reagents, supplies and add-on equipment from original equipment manufacturers.
 
 
 
Table of Contents : 
1. Overview 7
1.1 Objectives of the Report 7
1.2 Methodology 8
1.3 Scope of the Report 8
1.4 Executive Summary 9

2 IVD Clinical Hematology Analyzer Market 11
2.1 Introduction 11
2.2 Key Product Segments 17
2.2.1 Hematology and Associates Instruments 17
2.2.1.1 Hematology Analyzers 17
2.2.1.2 Hematology Instruments Offerings by Major Players 17
2.2.1.2.1 Hematology Reagents and Controls 18
2.2.1.2.2 Hematology Point of Care Instruments 19
2.2.1.3 Flow Cytometers 20
2.2.1.3.1 Flow Cytometry Technology Platforms 20
2.2.1.3.2 Clinical Applications of Flow Cytometry 20
2.2.1.3.2.1 Leukocyte Analysis 20
2.2.1.3.2.2 Immunophenotyping of Leukemias and Lymphomas 21
2.2.1.3.2.3 Neutropenia 21
2.2.1.3.2.4 Platelet Analysis 21
2.2.1.3.2.5 T Cell Subsets 22
2.2.1.3.2.6 Reticulocyte Count 22
2.2.1.3.3 Flow Cytometry Market Growth 22
2.2.1.3.3.1 Applications 23
2.2.1.3.3.2 Market Size 23
2.2.1.3.3.3 Instrumentation Preferences 24
2.2.1.3.3.4 Reagent Selection and Use 24
2.2.1.3.3.5 Instrument Manufacturers 25
2.2.1.3.3.6 Future Directions of Flow Cytometry 26
2.2.1.4 Coagulation Analyzers 26
2.2.1.4.1 Coagulation Market Size 27
2.2.1.4.2 Prothrombin Time Test 28
2.2.1.4.3 Activated Partial Thromboplastin Time (APTT) 28
2.2.1.4.4 Clinical Advantages of Coagulation Testing 29
2.2.1.4.5 Coagulation Instruments 30
2.2.1.4.5.1 Roche Diagnostics 30
2.2.1.4.5.2 Avocet Medical 31
2.2.1.4.5.3 International Technidyne Corporation 31
2.2.1.4.5.4 Cardiovascular Diagnostics 32
2.2.1.4.5.5 Diagnostica Stago’s STA-R Evolution 32
2.2.1.4.5.6 Other Companies 33
2.2.1.4.5.7 Coagulation Reagents 34
2.2.1.5 Hemoglobinometers 34
2.2.1.6 Slide Stainers 34
2.2.1.7 Differential Counters 36
2.2.1.8 Hematology Stains 37
2.3 Blood Components 37
2.3.1 Complete Blood Count (CBC) 37
2.3.2 Red Blood Cells (RBCs) 38
2.3.3 White Blood Cells (WBCs) 38
2.3.4 Platelets 39
2.3.5 Hematocrit (HCT) 39
2.4 Hematology Tests 39
2.5 The Coulter Principle 40
2.6 Blood Collection 40
 
 For More Information, Kindly Visit :
http://www.aarkstore.com/reports/Hematology-Analyzer-Instrumentation-and-Reagent-Markets-1314.html

Dental Equipment Market – Aarkstore Enterprise

The dental devices report forecasts the size of global dental equipment and consumables market over the period 2009 – 2014. The report analyses the key trends of the market, and segments the global dental equipment and consumables market by components and into various geographic regions (with the market size for each of these regions). Further, it discusses the key market drivers, restraints and opportunities of the global dental equipment and consumables market.

The global dental equipment and consumables market is estimated to be $26 billion by 2014, growing at a CAGR of 6.8%. The market is expected to grow because of the tremendous demand for dental biomaterial and dental implants. It is expected that the market for dental implants and dental biomaterials will grow at an overall CAGR of 12.2% and 10.5% respectively from 2009 – 2014. The main driving element for global dental equipment market is the advancement in technologies that are available to dentists’ for treating their patients.

The growth of this market is expected to be highest in the U.S. and EU where the generation of aging baby boomers can afford the quality but expensive dental procedures. This is also expected to be a catalyst for the growth and popularity of cosmetic treatments and implants along with the increasing demand for better orthodontic products by youngsters. The emerging technology will reduce the overall turnaround time for dental procedures while improving efficiency of the dental practitioners. For example, introduction of CAD/CAM has reduced designing time for dental crowns and bridges and 3D imaging techniques have improved patient diagnosis and procedure planning. Improvements in the field of dental biomaterials and tissue regenerative material have enabled the dentists to offer more natural and longtime dental solutions. Dentists are now educating their patients about dental products, which has helped in improving customer awareness about products and the latest available technologies. Changing consumer needs and a shift towards cosmetic dentistry will drive the market for hi-end dental solutions.

Stiff competition exists among the industry participants due to product differentiation, technology and pricing. This is more evident among dental companies resulting in companies adopting strategies like technology integration, product improvement and re-branding.

Global Dental Devices and Consumables Market Report

The report segments the Global Dental Devices and Consumables Market based on:

• General and diagnostic devices market by product
• Treatment based devices market by product
• Other dental devices market by product
• Dental consumables market by product

While existing reports have attempted to study end-user attitudes and demographics, they do not provide a complete picture from the industry’s perspective. This report on “Global Dental Devices and Consumables Market” analyzes the market dynamics exclusively from the industry point of view. The report aims at providing a two-dimensional picture of the market by focusing on all aspects of the dental devices market as well as the dental consumables reporting the key trends, which are further analyzed at the micro market levels. The report also includes segments for dental diagnostic devices, dental treatment based devices, consumables and other dental devices market.

Each segment of the report will provide market tables, drivers, restraints and opportunities along with the key players and competitive landscape. This report will also provide more than 100 market tables for various geographic regions covering the sub-segments and micro-markets. In addition, the report provides over 45 company profiles for each of its sub-segments, such as dental chair manufacturers, implants manufacturers, other devices manufacturers etc.

THE REPORT ANSWERS THE FOLLOWING QUESTIONS

• What are the key market dynamics influencing the market trends?
• Who are the target audience driving the market growth in each of the micro-market?
• Where are key opportunities available to the market players to capitalize on?
• What are the competitive strategies increasingly adopted to combat competition?

What makes our report unique?
• Provision of longest market segmentation in the industry.
• The report provides analysis of patents and more than 45 company profiles giving a competitive outlook.
• The report includes market data for segments such as tools, services and applications for the major geographies – U.S., Europe, Asian and Rest of the World.
• The high level analysis provided by the report analyzes the market prospective for different major market segments along with the identification of opportunities.
• Provides competitive analysis of the major segments and focuses on the global market players and key developments – equipment, devices and technology.

Key questions answered
• Which are the high growth market segments in terms of devices and consumables?
• What are the market forecasts and estimates from the period 2009-14?
• What are the major drivers and opportunities in the market?
• What is the competitive outlook, what are the major tools and services, who are the major players in the market segments?

For More Information, Kindly Visit :
http://www.aarkstore.com/reports/Dental-Equipment-Market-2009-2014–27514.html

Top 10 Medical Device Technology – Aarkstore Enterprise

Technological innovations in the medical device industry have led to a radical transformation in patient care. This report identifies the sectors with the industry’s most important developments related to patient care, clinical outcomes, and new product development. While the scope of the report is limited to the top ten technologies only, it covers almost the entire medical device market.

Scientific and medical technology breakthroughs – such as minimally invasive surgery (MIS) – have accelerated the accuracy of clinical outcomes and have also reduced recovery times and the medical costs borne by patients. This has led to radical transformation in patient care.

IT integration in medical imaging and medical devices has given a significant boost to the healthcare industry, a trend that is apparent in the market growth of drug eluting stents and telemedicine technologies. The markets covered in the report have a current potential of $454.3 billion and are expected to grow at a CAGR of 9.8% between 2009 and 2014.

Market estimates and forecast
The report provides in-depth market estimates and forecast for top ten medical device technologies as follows:
• Diagnostic imaging (nuclear imaging, interventional radiology, capsule endoscopy and others)
• Drug delivery (needle free injections, transdermal systems, inhalation system, infusion system)
• Molecular diagnostics (biosensors, proteomics, nanotechnology, and others)
• Mobility aid technologies
• Minimal/non-invasive surgery (stents, bariatric surgery, medical robotics and others)
• Micro-fluids and MEMS (Miniature medical pressure sensors, bio chips, protein chips)
• Non-invasive monitoring (continuous blood glucose monitoring)
• Biomaterials (bionic limbs, joint replacement, antimicrobial wound dressing and others)
• Bio-implants (neurostimulation and others)
• Tele-medicines

Each section will provide market data, market drivers, trends and opportunities, top-selling products, key players, and competitive outlook. This report will also provide more than 100 market tables for various geographic regions covering the sub-segments and micro-markets. In addition, the report also provides 50 company profiles for each of its sub-segments.
What makes our reports unique?
• We provide the longest market segmentation chain in this industry- not many reports provide market breakdown upto level 5.
• Each report is about 250 pages with 100+ market data tables, 40 competitive company profiles, analysis of 300 patents and minimum 50 micro markets, which are collectively exhaustive and mutually exclusive.
• No single report by any other publisher provides market data for all the segments viz products, services, applications, ingredients, technology, and stakeholders in a single report for all the four geographies – US, Europe, APAC, ROW.
• We provide 10% customization – Research shows that more than 40% of the times, clients do not get the specific intelligence they need in multi-client market research reports. We offer 10% customization in our reports at no extra cost. Get the exact market intelligence you require with real value for money.
• 15 pages of high level analysis including benchmarking strategies, best practices and the market’s cash cows (BCG matrix). We conduct detailed market positioning, product positioning and competitive positioning. Entry strategies, gaps and opportunities are identified for all the stakeholders.
• Comprehensive market analysis for pharmaceutical and biotech companies, medical device manufacturers, pharma-research labs, doctors, physicians and hospitals, medical/pharma associations, retailers and super-retailers, technology providers, and research and development (R&D) companies.

Key questions answered
• Which are the high-growth segments/cash cows and how is the market segmented in terms of applications, products, services, ingredients, technologies, and stakeholders?
• What are market estimates and forecasts; which markets are doing well and which are not?
• Where are the gaps and opportunities; what is driving the market?
• Which are the key playing fields? Which are the winning edge imperatives?
• How is the competitive outlook; who are the main players in each of the segments; what are the key selling products; what are their strategic directives, operational strengths and product pipelines? Who is doing what?

Powerful Research and Analysis
The analysts working come from renowned publishers and market research firms, globally, adding their expertise and domain understanding. We get the facts from over 22,000 news and information sources, a huge database of key industry participants and draw on our relationships with more than 900 market research companies across the world. We are inspired to help our clients grow by providing qualitative business insights with our huge market intelligence repository.

For More Information, Kindly Visit :
http://www.aarkstore.com/reports/Top-10-Medical-Device-Technology-27527.html

Evolving Trends in Biopharmaceutical Licensing: Deal assessments, drivers and resistors – Aarkstore Enterprise

Evolving Trends in Biopharmaceutical Licensing: Deal assessments, drivers and resistors

Large Pharma companies have become heavily dependant upon alliances and in-licensing to gain access to technologies/new molecular entities from Biopharma. This reliance has strengthened Biopharma’s bargaining position, and is reflected in negotiation tactics which aim to expand their role beyond product discovery and development towards an active participation in the the future of their products. This is emphasized by the growing complexity of licensing deals, as Biopharma attempts to secure marketing and commercialization rights within partnership deals.

Furthermore, recent increases in internal Biopharma consolidation are an indicator of the ability of well-established Biopharma companies to effectively compete against traditional big Pharma.

‘Evolving Trends in Biopharmaceutical Licensing’ is a report provides a detailed analysis of licensing strategies in the biopharmaceutical industry over the 2001-08 period. This report examines the growth of the biopharmaceutical industry, deal-making trend data, drivers and challenges facing biopharmaceutical licensing, and profiles of biopharmaceutical licensing among leading companies. The future prospects of the industry are assessed and the potential impact of political/regulatory factors upon licensing and alliances is identified. This report also investigates the influence of the recent upsurge in M&A activity and provides recommendations on the strategies that can sustain future growth.

Key Findings

• Several top-ranked Biopharma companies have matched the consistent sales growth of major traditional pharma companies. A key component of this success has been the increasing reliance of big Pharma to improve R&D productivity and rejuvenate sales of marketed portfolios through licensing and partnership deals.
• Big Pharma has been acquiring Biopharma companies at an increasing rate, resulting in this becoming the fastest-growing M&A sector in 2008 with deal values up 87%. Intense competition and financial uncertainty has also prompted a surge in biopharma consolidation, with 52 biopharma/biopharma deals in 2007.
• Considerable potential for Biopharma licensing deals still exists, particularly within the OAD class of drugs and non-invasive insulin drug delivery technologies.
• The total deal size of early-stage alliances with biopharma has increased six-fold, with total deal values in 2007 estimated at $18bn. This has been driven by the relatively lower costs of discovery and lead development, despite the higher risk of failure.
• Co-development/co-promotion deals accounted for 30% of licensing deals over 2006-07. Licensing deals will continue to become more complex due to biopharma’s desire to remain involved in their product lifecycle beyond the stages of discovery and development

Use this report to…

• Examine the licensing landscape of the biopharma industry with this report’s analysis of Biopharma and Pharma licensing and alliance activity and an examination of specific approaches utilized by both sectors.
• Discover the drivers and challenges facing Biopharma licensing, understand how Biopharma companies are preparing to exploit new opportunities and assess deal-making trends across clinical trials phases and key therapeutic areas.
• Evaluate the strategies of leading companies involved in biopharmaceutical licensing with this report’s analysis of deal activities amongst leading players and identify the changing dynamics of Biopharma/Pharma partnerships.
• Assess the future prospects of the Biopharma industry and how current market and political/regulatory factors will impact the dynamics of licensing and alliances, as well as potential strategies for sustaining growth.

Explore issues including…

• Biopharmas reduced reliance on Pharma. Biopharma is sustaining its efforts to increase its role outside of product development/discovery to become actively engaged in the future of their products. As such, it is becoming increasingly difficult to differentiate big Pharma from major Biopharma companies.
• Optimizing revenue potential. Biopharma are increasingly targeting high value therapy areas, such as oncology and inflammatory disease, bringing them into direct competition with major Pharma.
• Future competitive strategies. With licensing deals increasing in value and complexity, Biopharma companies are looking to increase their involvement by forming long-term, partnership-based relationships. This active engagement in licensing deals will typically involve the negotiation of equity investment and the co-promotion and co-marketing of a drug that allows Biopharma to generate additional downstream revenues.
• Drug development potential. The emergence of several new Biopharma companies with innovative technology platforms has created immense potential for intra-Biopharma licensing trends to continue developing novel drugs that can successfully differentiate themselves within the marketplace.

Discover…

• How will the increasing competition for attractive Biopharma licensing candidates affect deal terms and values?
• How can Biopharma companies improve their licensing strategies to ensure future growth?
• What have been the major trends in licensing agreements between Biopharma and Pharma over 2001-08?
• Which strategies have Biopharma used to reduce their reliance on Pharma?
• How has the value, volume and competition for Biopharma licensing deals changed over 2001-08?
• What have been the strategies of successful Biopharma and Pharma deal-makers?
• Why are Biopharma and Pharma increasingly adopting M&A strategies instead of entering into licensing agreements?

For more information, kindly visit :
http://www.aarkstore.com/reports/Evolving-Trends-in-Biopharmaceutical-Licensing-Deal-assessments-drivers-and-resistors-13949.html

Negotiating the Emerging Biosimilars Landscape: Key Developments in the Regulatory Environment

As regulatory obstacles to biosimilars development have become increasingly resolved, a growing number of opportunities have been created for generics companies in the biopharmaceutical market, which according to IMS data was valued at $85.9 billion in 2007. Conservative projections estimate that sales of biopharmaceutical products will exceed $135 billion by 2011. With some of the earliest biopharmaceuticals having already lost patent protection, the originators of biopharmaceutical products are facing intense competition from generics developers. In response, originators are resorting to a range of defensive tactics, including the reformulation of existing products to improve efficacy, the implementation of more efficient delivery systems and the pursuit of high-level intellectual property (IP) battles.

‘Negotiating the Emerging Biosimilars Landscape’ is a new report published by Business Insights that examines the structure of the biopharmaceutical industry and the strategic approaches taken to alleviate the threat posed by the biosimilar market. The key factors affecting market access within the biosimilars market are assessed and the latest issues surrounding bioequivalence are examined. This report also provides a comprehensive review of the current legislative and regulatory positions of key geographic regions in addition to evaluating their anticipated future legislative changes and outcomes.

Key Findings

European Union guidelines have been prepared which authorise the use of specific therapeutic biopharmaceutical medicines as biosimilars. However, despite the range of current European guidelines produced by the EMEA, many European governments have issued laws prohibiting the automatic substitution of original products.

No approval pathway for biosimilars (FOB) exists in the USA, and one is unlikely to exist before 2010. A complex range of Acts and Bills have failed to resolve a number of outstanding legal and regulatory issues.

India’s biopharmaceutical industry is projected to grow to almost $5 billion by the end of 2010, representing annual growth in excess of 30%. However, despite WTO membership and recent advances in compliance with international regulatory/intellectual property laws, there remains no formal regulatory framework for biosimilars in India or China.

Health Canada has not yet publicly announced a legal or regulatory framework for biosimilar approval, and no legal framework for biosimilars currently exists in Japan. New regulatory frameworks and biosimilar guidelines are currently under development in both countries.

Use this report to…

• Identify and respond to the challenges and threats posed by the emergence of the biosimilars industry with this report’s examination of key trends and strategic approaches used by the biopharmaceutical industry to protect market share and intellectual property.
• Examine details of expired patents or impending patent expiries for first-gen biopharmaceuticals derived from recombinant DNA such as interferons, human insulin and insulin analogs, monoclonal antibodies (Mab) growth hormone and epoietins.
• Evaluate the legislative and regulatory requirements for biosimilars across key geographic regions including Europe, the US, Japan, Australia, Canada as well as the strategically important emerging markets of China and India.
• Assess the factors affecting biosimilar market access with this report’s analysis of the drivers and restraints to biosimilar approval, use and uptake, in addition to an investigation of the problems associated with determining bioequivalence.

Explore issues including…

Impending patent expiries. The critical challenge facing the biopharmaceutical industry is the expiry or pending expiry of patents for first generation biopharmaceuticals derived from recombinant DNA such as interferons, growth hormone and epoietins.

Defensive strategies. As part of efforts to protect the market share of products with impending patent expiries, originator biopharmaceutical companies have begun to protect intellectual property and engage in strategic alliances, joint ventures and mergers between themselves and major pharma companies.

Geographical disparities in biosimilar legislation. Different geographic regions have varying legislative approaches to the regulation and/or approval of biosimilars. Such discrepancies often lead to misunderstandings and can result in complexity and complication during the approval process.

Discover…

• Which biopharmaceutical companies are at risk from product patent expires?
• What is the status of the analytical techniques used for determining bioequivalence?
• What tactics prove most effective for originator biopharmaceutical companies who wish to protect their market position?
• What effect the market entry of second generation biopharmaceuticals by originator companies have on the biosimilars market?
• What are the growth drivers and restraints of the biosimilars market?
• How are global healthcare costs influenced by biosimilar market entry prospects?
• What is the current legislative and regulatory status of biosimilars in Europe and the US?
• How will China and India influence the biopharmaceutical and biosimilars market in the future?

For more information, kindly visit :
http://www.aarkstore.com/reports/Negotiating-the-Emerging-Biosimilars-Landscape-Key-Developments-in-the-Regulatory-Environment-13944.html

Micro- and Nanomedicine: Technologies, Applications, Industry, and Markets Worldwide – Aarkstore Enterprise

This report details the current products and technologies under development and on the market with medical applications of nanotechnology and microelectromechanical systems (MEMS). The report details the current markets and their actual penetration by micromedical and nanomedical applications. The technologies and applications under development are critically analyzed to identify the technological, market, regulatory and other hurdles that developers must be overcome for products to achieve commercialization. Opportunities are revealed for development of specific applications. Nearly 100 companies are profiled for their current activities and competitive outlook, and many additional companies are referenced throughout the report.

For more information, kindly visit :
http://www.aarkstore.com/reports/Micro-and-Nanomedicine-Technologies-Applications-Industry-and-Markets-Worldwide-2050.html

Products, Technologies, Markets and Opportunities in Ophthalmology Surgical, Diagnostic, Device and Drug Markets Worldwide, Forecasts 2004 – 2012- Aarkstore Enterprise

This report details worldwide the incidence and prevalence by country/region of vision disorders (myopia, hyperopia, presbyopia, glaucoma, cataracts and retinal disease), and details the current and projected market for diagnostic and therapeutic products in the management of these vision disorders, including general vision diagnostics, diagnostics for glaucoma, corneal and retinal disorders, and therapeutic options for these disorders including use of pharmaceuticals, surgery and devices. The report details current products and technologies in use and the status of development of novel products under development. The report details the clinical and technology developments underlying this huge and evolving worldwide market, with data on products in development and on the market; market size and historic/forecast 2004-2012 (actual data for 2006/2007); competitor market shares; competitor profiles; and market opportunity. Separate size, growth and competitor share data are presented for the U.S., individual western European countries (UK, Germany, France, BeNeLux, Italy and Spain), Japan and other key international markets; Asia (India, Korea, Australia, Russia and China), the Americas (Canada, Mexico, Brazil) and Middle East and Africa categories. The report profiles 103 companies, with detailed product development, current positions and future outlook for major competitors, and brief profiles of smaller or more development stage companies with noteworthy novel or advanced research activities in the market.

The report establishes the market size for key international markets (as indicated above) for major technology segments as a baseline for and projecting growth in the market over a ten-year forecast. The report also assesses and projects the composition of the market (shifts in share based on technology) as technologies gain or lose relative market performance over this period.

For more information, kindly visit :
http://www.aarkstore.com/reports/Products-Technologies-Markets-and-Opportunities-in-Ophthalmology-Surgical-Diagnostic-Device-and-Drug-Markets-Worldwide-Forecasts-2004-2012-2058.html

Emerging Trends, Technologies and Opportunities in the Markets for Orthopedic Biomaterials, Worldwide – Aarkstore Enterprise

Worldwide Surgical Sealants, Glues and Wound Closure Market, 2007-2011 – Aarkstore Enterprise

This report details the complete range of sealants & glues technologies used in traumatic, surgical and other wound closure, from tapes, sutures and staples to hemostats, fibrin sealants/glues and medical adhesives. The report details current clinical and technology developments in this huge and rapidly growing worldwide market, with data on products in development and on the market; market size and forecast; competitor market shares; competitor profiles; and market opportunity.

This report is a market and technology assessment and forecast of products in wound closure. The report details the current and emerging products, technologies and markets involved in wound closure and sealing using sutures and staples, tapes, hemostats, fibrin and sealant products and medical adhesives. The report provides a worldwide current and annual forecast to 2011 of the markets for these technologies, with particular emphasis on the market impact of new technologies through the coming decade. The report provides specific forecasts and shares of the worldwide market by segment for the U.S., Europe (United Kingdom, German, France, Italy, BeNeLux), Latin America, Japan and Rest of World.

The report provides background data on the surgical, disease and traumatic wound patient populations targeted by current technologies and those under development, and the current clinical practices in the management of these patients, including the dynamics among the various clinical specialties or subspecialties vying for patient population and facilitating or limiting the growth of technologies.

The report establishes the current worldwide market size for major technology segments as a baseline for and projecting growth in the market over a ten-year forecast. The report also assesses and projects the composition of the market as technologies gain or lose relative market performance over this period.

For more information, kindly visit :
http://www.aarkstore.com/reports/Worldwide-Surgical-Sealants-Glues-and-Wound-Closure-Market-2007-2011-2068.html